The Board of Directors of ACROMEC Limited announced that, following a preliminary review of the unaudited financial results of the Group for the financial year ended 30 September 2018, the Group is expected to report losses for fiscal year 2018. This was attributable to additional cost incurred on the Group's project on the construction of a pharmaceutical plant in Tuas. This project has been closed and completed in fiscal year 2018.